Demant (DEMANT DC) lifts its FY26 organic growth guidance to between 7-8% (prev. guided 6-7%) and EBIT before special items between DKK 4.7-5bln (prev. guided DKK 4.4-4.8bln); also resumes share buybacks, expects DKK 3bln of buybacks by end-2027

Guidance raises of this size at a large-cap healthcare name tend to be received as confirmation rather than surprise when they follow a period of already firm trading; the more telling cases historically have been mid-cycle lifts against a sceptical consensus, which force estimate revisions across the sell side rather than mere top-end nudges. The organic growth component is the cleaner signal, since it strips out M&A and currency noise, and in the hearing healthcare space the read-across to peers has typically been limited by divergent exposure to retail versus wholesale channels. The resumption of buybacks alongside a guidance raise is the stronger part of the message: managements that restart capital return after a pause are usually signalling balance sheet comfort and reduced M&A appetite, a pattern that has generally been received more durably than guidance arithmetic alone. What matters next is whether the raise is volume-led or price/mix-led, which the next trading statement should clarify, and whether the buyback pace disclosed in interim filings matches the announced envelope. Hearing aid names have a history of sharp de-ratings on volume disappointments in the consumer channel, so the composition of the growth beat is the operative question rather than its headline size.